Product/Composition:- | PPIs + Clarithromycin + Amoxicillin tablets |
---|---|
Strength:- | (PPI): 30 mg + Amoxicillin: 500 mg + Clarithromycin: 500 mg |
Form:- | Tablets |
Reference Brands:- | Prevpac(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
PPIs bind to stomach H+/K+ ATPase enzymes, reducing acid secretion, creating a less hospitable environment for H. pylori. Clarithromycin and Amoxicillin target and eliminate the bacteria. The combination effectively eradicates H. pylori, relieves ulcers, and prevents gastric cancer. Benefits include symptom relief, mucosal healing, and reduced recurrence.
PPIs combined with clarithromycin and amoxicillin tablets are approved in the US by the FDA and in the EU via EMA for Helicobacter pylori eradication. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical trial and quality data for timely approval, while the EMA ensures compliance with regional safety and manufacturing standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional regulations supports swift approval, safe use, and worldwide availability, helping healthcare providers effectively treat H. pylori infections and prevent gastric complications globally.